ZA201201195B - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof

Info

Publication number: ZA201201195B
Authority: ZA; South Africa
Prior art keywords: ectodomain; erbb3; antibodies against; antibodies
Prior art date: 2009-08-21

Application number

ZA2012/01195A

Other languages

English (en)

Inventor

Birgit Schoeberl

Ulrik Nielsen

Michael Feldhaus

Original Assignee

Merrimack Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-21

Filing date

2012-02-17

Publication date

2015-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201201195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-02-17 Application filed by Merrimack Pharmaceuticals filed Critical Merrimack Pharmaceuticals

2015-07-29 Publication of ZA201201195B publication Critical patent/ZA201201195B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA2012/01195A 2009-08-21 2012-02-17 Antibodies against the ectodomain of erbb3 and uses thereof ZA201201195B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23579909P	2009-08-21	2009-08-21
PCT/US2010/046364 WO2011022727A2 (fr)	2009-08-21	2010-08-23	Anticorps contre lectodomaine de erbb3 et leurs utilisations

Publications (1)

Publication Number	Publication Date
ZA201201195B true ZA201201195B (en)	2015-07-29

Family

ID=43607614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA2012/01195A ZA201201195B (en)	2009-08-21	2012-02-17	Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country	Link
EP (1)	EP2467164A2 (fr)
JP (1)	JP5752687B2 (fr)
KR (1)	KR20120059568A (fr)
CN (1)	CN103002912A (fr)
AU (1)	AU2010284018C1 (fr)
BR (1)	BR112012003809A2 (fr)
CA (1)	CA2771744A1 (fr)
CR (1)	CR20120108A (fr)
DO (1)	DOP2012000044A (fr)
EA (1)	EA201200195A1 (fr)
EC (1)	ECSP12011740A (fr)
IL (1)	IL218097A0 (fr)
IN (1)	IN2012DN01518A (fr)
MA (1)	MA33582B1 (fr)
MX (1)	MX336091B (fr)
NI (1)	NI201200027A (fr)
PE (1)	PE20121585A1 (fr)
SG (1)	SG178509A1 (fr)
TN (1)	TN2012000057A1 (fr)
WO (1)	WO2011022727A2 (fr)
ZA (1)	ZA201201195B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2716301T3 (en)	2007-02-16	2017-07-31	Merrimack Pharmaceuticals Inc	ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
CN105999263B (zh) *	2009-11-13	2021-06-29	第一三共欧洲有限公司	用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
UA107821C2 (en)	2009-12-22	2015-02-25	Roche Glycart Ag	Antibody her3 and its application
CA2792327C (fr)	2010-03-11	2019-09-24	Merrimack Pharmaceuticals, Inc.	Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples negatifs et de type basal
ES2566602T3 (es)	2010-04-09	2016-04-14	Aveo Pharmaceuticals, Inc.	Anticuerpos anti-ErbB3
PL2606070T3 (pl)	2010-08-20	2017-06-30	Novartis Ag	Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
IT1402149B1 (it) *	2010-10-04	2013-08-28	Ist Fisioterap Ospitalroma	Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
AU2011324871B2 (en)	2010-11-01	2016-05-19	Symphogen A/S	Anti-HER3 antibodies and compositions
EP2699602B1 (fr)	2011-04-19	2017-03-01	Merrimack Pharmaceuticals, Inc.	Anticorps anti-igf-1r et anti-erbb3 bispécifiques
CA2840461A1 (fr)	2011-06-20	2012-12-27	Kyowa Hakko Kirin Co., Ltd.	Anticorps anti-erbb3
HK1200468A1 (en)	2011-09-30	2015-08-07	Regeneron Pharmaceuticals, Inc.	Anti-erbb3 antibodies and uses thereof
US9273143B2 (en)	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9828635B2 (en)	2011-10-06	2017-11-28	Aveo Pharmaceuticals, Inc.	Predicting tumor response to anti-ERBB3 antibodies
AU2012335543C1 (en) *	2011-11-09	2017-12-14	Beijing Cotimes Biotech Co., Ltd.,	HER3 antibodies and uses thereof
SG11201402783YA (en)	2011-12-05	2014-06-27	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
JP2015509492A (ja) *	2012-02-22	2015-03-30	ユー３・ファーマ・ゲーエムベーハー	Ｈｂ−ｅｇｆ結合タンパク質およびｅｇｆｒ阻害剤の組合せ
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) *	2013-10-17	2016-08-11	Sanford-Burnham Medical Research Institute	Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (fr)	2013-12-27	2015-07-02	Merrimack Pharmaceuticals, Inc.	Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
ES2816624T3 (es)	2014-02-28	2021-04-05	Merus Nv	Anticuerpos que se unen a EGFR y ERBB3
CN105367657B (zh) *	2014-08-14	2019-09-13	上海生物制品研究所有限责任公司	抗her3抗体、其制法及其应用
CA2959716A1 (fr)	2014-09-08	2016-03-17	Yeda Research And Development Co. Ltd.	Anticorps anti-her3 et leurs utilisations
AU2015313811A1 (en)	2014-09-08	2017-04-06	Yeda Research And Development Co. Ltd.	Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
HRP20210483T1 (hr)	2015-10-23	2021-07-09	Merus N.V.	Vezujuće molekule koje inhibiraju rast raka
KR20260006707A (ko)	2017-03-31	2026-01-13	메뤼스 엔.페.	NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB2 및 ErbB3 결합 이중특이적 항체
AU2018271157C1 (en)	2017-05-17	2021-11-18	Merus N.V.	Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
CA3072267A1 (fr)	2017-08-09	2019-02-14	University Of Saskatchewan	Agents de liaison a her3 et utilisations associees
DK3665198T3 (da)	2017-08-09	2025-04-28	Merus Nv	Antistoffer, der binder egfr og cmet
GB201804094D0 (en) *	2018-03-14	2018-04-25	Ultrahuman Thirteen Ltd	ERBB3 Binding agents
WO2019241893A2 (fr) *	2018-06-22	2019-12-26	Crd Pharmaceuticals Inc	Anticorps anti-her3 et ses utilisations
CN116133694A (zh) *	2020-10-14	2023-05-16	江苏恒瑞医药股份有限公司	抗her3抗体和抗her3抗体药物偶联物及其医药用途
IL303030A (en) *	2020-11-20	2023-07-01	Actinium Pharmaceuticals Inc	Her3 radioimmunotherapy for the treatment of solid cancers
KR20240021294A (ko) *	2021-06-15	2024-02-16	베이징 시노타우 바이오-파마슈티컬스 테크놀로지 씨오., 엘티디.	항-her3 항체, 이를 함유하는 항체-약물 접합체 및 그 용도
WO2023198138A1 (fr) *	2022-04-13	2023-10-19	上海翰森生物医药科技有限公司	Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2716301T3 (en) *	2007-02-16	2017-07-31	Merrimack Pharmaceuticals Inc	ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF

2010
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/fr not_active Ceased
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 CA CA2771744A patent/CA2771744A1/fr not_active Abandoned
- 2010-08-23 EP EP10810721A patent/EP2467164A2/fr not_active Withdrawn
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown

Also Published As

Publication number	Publication date
MX2012002172A (es)	2012-05-29
ECSP12011740A (es)	2013-02-28
NI201200027A (es)	2013-01-29
AU2010284018B2 (en)	2014-06-05
EA201200195A1 (ru)	2012-12-28
IL218097A0 (en)	2012-04-30
KR20120059568A (ko)	2012-06-08
PE20121585A1 (es)	2012-11-29
JP5752687B2 (ja)	2015-07-22
MA33582B1 (fr)	2012-09-01
WO2011022727A3 (fr)	2013-06-27
TN2012000057A1 (en)	2013-09-19
WO2011022727A2 (fr)	2011-02-24
AU2010284018C1 (en)	2015-10-15
CR20120108A (es)	2012-06-05
IN2012DN01518A (fr)	2015-06-05
SG178509A1 (en)	2012-04-27
DOP2012000044A (es)	2012-06-30
JP2013506622A (ja)	2013-02-28
EP2467164A2 (fr)	2012-06-27
MX336091B (es)	2016-01-08
BR112012003809A2 (pt)	2019-09-24
AU2010284018A1 (en)	2012-03-22
CN103002912A (zh)	2013-03-27
CA2771744A1 (fr)	2011-02-24

Publication	Publication Date	Title
ZA201201195B (en)	2015-07-29	Antibodies against the ectodomain of erbb3 and uses thereof
EP2494062A4 (fr)	2013-05-29	Anticorps anti-glp-1r et leurs utilisations
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
SMT202100676T1 (it)	2022-01-10	Anticorpi anti-cd277 e loro usi
SI2516468T1 (sl)	2016-06-30	Protitelesa proti flt3 in postopki uporabe istih
IL200373A0 (en)	2010-04-29	Antibodies against erbb3 and uses thereof
IL215291A0 (en)	2011-12-29	NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL216835A0 (en)	2012-02-29	Anti-vegf antibodies and their uses
ZA201107555B (en)	2012-12-27	Anti-17f antibodies and methods of use thereof
IL219801A0 (en)	2012-07-31	ANTI-C4.4a ANTIBODIES AND USES THEREOF
ZA201108310B (en)	2013-04-24	Blocking anti-dkk-1 antibodies and their uses
SG10201501285RA (en)	2015-04-29	Anti-alpha2 integrin antibodies and their uses
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
SI2493930T1 (sl)	2018-12-31	Izboljšana protitelesa proti humanemu fraktalkinu in njihova uporaba
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
GB0903151D0 (en)	2009-04-08	Antibody uses and methods
GB0906115D0 (en)	2009-05-20	Antibody and uses thereof